Myasthenia gravis (MG) is a rare, chronic autoimmune disorder that disrupts the communication between nerves and muscles. It ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Members of the European Parliament, researchers, patient advocates, national experts, and representatives from the biotech ...

leading researchers to believe that myasthenia gravis may be caused by varying underlying mechanisms for different people. Researchers at UC San Diego's School of Biological Sciences used a ...

We came across a bullish thesis on argenx SE (ARGX) on Substack by FluentInQuality. In this article, we will summarize the ...

Myasthenia gravis and CIDP involve the direct effects ... and platelet-bound autoantibodies are not identified in all patients. Clearance mechanisms not based on FcRn, such as the ...

DelveInsight's "FABHALTA Market Size, Forecast, and Market Insight Report" highlights the details around FABHALTA, an oral ...

Q1 2025 Earnings Call Transcript May 1, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $4.9, expectations were ...

So we really are looking at oral and non-oral mechanisms ourselves ... question I've been thinking about for a while on the myasthenia gravis market dynamic. Specifically, a lot of times when ...